Allogene Therapeutics
Bob To has extensive experience in the biotechnology and pharmaceutical industries, holding various leadership and scientific positions. At Allogene Therapeutics, Bob serves as a Director and previously held the role of Associate Director in External Testing Oversight. Bob's career at Bayer includes positions such as Senior Manager of Method Validation and Associate Director of QC Conformance, among others. Prior experience at XOMA (US) LLC involved roles as Senior Scientist and Manager in Bioassay and Immunoassay Development. Bob also worked as a Scientist at Exelixis and served as Principal Scientist at Novartis, formerly known as Chiron.
This person is not in the org chart
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.